Ultragenyx Pharmaceutical (RARE) Gains from Investment Securities (2013 - 2025)

Ultragenyx Pharmaceutical (RARE) has 13 years of Gains from Investment Securities data on file, last reported at -$693000.0 in Q4 2025.

• Gains from Investment Securities for Q4 2025 came in at -$693000.0, up 42.35% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (up 6.95% YoY), and the FY2025 annual result was $2.0 million, changed 0.0% from the prior year.
• Gains from Investment Securities fell to -$693000.0 in Q4 2025 per RARE's latest filing, from $1.6 million in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $4.5 million in Q2 2023 and troughed at -$1.8 million in Q3 2023.
• A 5-year average of $558600.0 and a median of $39000.0 in 2022 frame the typical range for Gains from Investment Securities.
• On a YoY basis, Gains from Investment Securities climbed as much as 34480.0% in 2023 and fell as far as 434.29% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $455000.0 in 2021, then sank by 102.2% to -$10000.0 in 2022, then soared by 34480.0% to $3.4 million in 2023, then sank by 134.96% to -$1.2 million in 2024, then soared by 42.35% to -$693000.0 in 2025.
• Business Quant data shows RARE's Gains from Investment Securities at -$693000.0 in Q4 2025, $1.6 million in Q3 2025, and $88000.0 in Q2 2025.